Hearts & Minds Blog

NLA 2014 Scientific Sessions: Placing the Focus on Statin Intolerance

Roger Newton, PhD, FAHA

Executive Chairman and Chief Scientific Officer

Marianne Andreach

Senior Vice President, Strategic Marketing and Product Planning

As members of the Esperion team developing ETC-1002—a unique, first-in-class, orally available, once-daily small molecule designed to lower low density lipoprotein cholesterol (LDL-C) levels, particularly in individuals with hypercholesterolemia who are intolerant to statins—we are excited any time there is a specific emphasis on, or a new development in, this underserved patient population. In the U.S., it is estimated that up to 20 percent of adults taking statins for elevated LDL-C are intolerant to the therapy. Most statin intolerance is related to muscle pain or… more

“The IPO Age: Onward and Upward” — Insights from the BioCentury TV Roundtable

Tim Mayleben

President and Chief Executive Officer

Recently, I had the pleasure of participating in a roundtable, “The IPO Age: Onward and Upward,” to review how the recent spate of biotech IPOs belies the earlier struggle to finance trials and product development. I was joined by fellow biotech CEOs, Jeff Abbey of Argos and Scott Koenig of MacroGenics, for an engaging and timely conversation that was featured on BioCentury TV. If you haven’t had the opportunity to watch yet, please check it out here.  To build upon this robust discussion, I wanted… more

ACC.14: Spotlighting the Importance of Finding New Therapies for Statin Intolerant Patients

Roger Newton, PhD, FAHA

Executive Chairman and Chief Scientific Officer

Late last month, the American College of Cardiology (ACC) held its 63rd Annual Scientific Session & Expo with more than 13,000 cardiovascular experts coming together in Washington, D.C. As I have for many years, I traveled to ACC.14 with my Esperion colleagues to hear firsthand the latest research findings in the prevention, diagnosis and treatment of cardiovascular disease (CVD). I especially enjoyed this year’s conference, given that I have spent my career researching and developing LDL-C lowering treatments, and that our lead product candidate, ETC-1002,… more

Providing an Alternative for LDL-C Lowering

Tim Mayleben

President and Chief Executive Officer

Brian Orelli’s recent article in BioWorld Insight, “Avoiding the PCSK9 frenzy with alternative drug targets,” highlights how the focus and excitement around the PCSK9 inhibitors reflects the high level of interest for effective alternatives to statins for low-density lipoprotein cholesterol (LDL-C) lowering. While the PCSK9 inhibitors—injectable biologic therapies—have demonstrated compelling efficacy, Orelli’s piece reminds us that hypercholesterolemia does not have a one-size-fits all solution. Physicians and patients want and need alternative therapeutic options. With the spotlight on the LDL-C lowering treatment pipeline, the team at… more

Looking Back on a Successful 2013 and a Glance Ahead at a Promising 2014

Tim Mayleben

President and Chief Executive Officer

Esperion had an incredible year in 2013 with more successes, both clinically and financially, than in any other year since we were founded in April 2008 as the new Esperion. We executed on all of our milestones – all toward our goal of bringing ETC-1002 to market. A unique, first-in-class, oral, once-daily investigational small molecule, ETC-1002 is designed to lower levels of low-density lipoprotein cholesterol (LDL-C) and avoid the side effects associated with existing LDL-C lowering therapies. Our goal is to develop ETC-1002 for the… more